In today’s briefing:
- Nihon Kohden (6849 JP): ¥10B Buyback Plan And Stock Split; Japan and US to Drive Business Growth
- Liquid Universe of European Ordinary and Preferred Shares: May‘24 Report
- Amgen Inc.: Will The Increased Spending on Research and Development (R&D) Pay Off? – Major Drivers
- HEC CJ Pharma (1558.HK)’s Merger Deal with Sunshine Lake Pharma – Almost No Investment Value
- CTSO: CytoSorbents reports 1st quarter 2024 financial results and highlighted STAR-T trial data presentation at the AATS conference.
- DYAI: Product Revenues Next Year
- AMS: 1Q24 Revenue Up, With Rhode Island Centers Coming on Stream in 2Q
- LTRN: Expanding Horizons into Asia
- Bio-Techne Corporation: Growth in the Cell and Gene Therapy Market & Improved Positioning In Spatial Biology Market! – Major Drivers
- Jazz Pharmaceuticals plc: Zanidatamab’s Differentiated Efficacy and Safety Profile & Other Major Drivers
Nihon Kohden (6849 JP): ¥10B Buyback Plan And Stock Split; Japan and US to Drive Business Growth
- In FY25, Nihon Kohden (6849 JP) guided for domestic revenue of ¥147B, up 3% YoY. The demand for patient monitors and treatment equipment is expected to remain steady.
- Nihon Kohden expects North America business to report a revenue CAGR of 11% (fastest among all the other regions) during FY24–27, outpacing mid-single-digit growth of the market.
- The company announced ¥10B buyback plan to repurchase up to 6M shares, representing 3.57% of total number of issued shares from August 5, 2024, to March 31, 2025.
Liquid Universe of European Ordinary and Preferred Shares: May‘24 Report
- Since mid-April, spreads have generally tightened across our European liquid universe of ordinary and preferred shares (12 have tightened, 7 widened). Views are unchanged.
- Recommended trades long preferred / short ordinary shares: Atlas Copco, Danieli, Grifols (see section on the company), Media-for-Europe, Sixt, Volkswagen.
- Recommended trades long ordinary / short preferred shares: Henkel, SSAB Svenska Stal, Roche.
Amgen Inc.: Will The Increased Spending on Research and Development (R&D) Pay Off? – Major Drivers
- Amgen Inc. witnessed strong growth in the Q1 of 2024 with total revenue increasing by 22% YoY. This was largely driven by strong volume growth, including over $900 million from the integration of Horizon Pharmaceuticals’ legacy portfolio.
- The growth was also supported by robust product sales from brands like Repatha, TEZSPIRE, EVENITY, Prolia, and BLINCYTO. Amgen projects full-year sales of approximately $500 million for Neulasta.
- The company has advanced many of its pipeline products; it awaits approval for tarlatamab, hopes to bring this innovative cancer solution to patients with small-cell lung cancer.
HEC CJ Pharma (1558.HK)’s Merger Deal with Sunshine Lake Pharma – Almost No Investment Value
- Sunshine Lake Pharma plans to privatize HEC CJ Pharma in the form of merger by absorption with conditions. After privatization, CJ Pharma will be delisted from the Stock Exchange.
- Sunshine Lake Pharma’s pipeline has been “disconnected” from the level of domestic biotech in recent years, and is completely lagging behind the average speed of innovative drug development in China.
- Due to “outdated” pipeline and lack of prospects, even if CJ Pharma is merged into Sunshine Lake Pharma, valuation performance of the new entity would be disappointing in the future.
CTSO: CytoSorbents reports 1st quarter 2024 financial results and highlighted STAR-T trial data presentation at the AATS conference.
- CytoSorbents is commercializing its E.U. approved CytoSorb blood purification technology to treat life-threatening conditions in the intensive care unit and cardiac surgery.
- The company also seeks U.S. and Canadian approval of a second product, DrugSorb-ATR, to reduce perioperative bleeding risk in patients on the blood thinner, ticagrelor, undergoing cardiac surgery.
- Data from the pivotal U.S. STAR-T trial presented at the AATS conference and recent KOL/Analyst/Investor day demonstrate a favorable benefit-to-risk profile of DrugSorb-ATR to reduce serious bleeding in patients undergoing isolated CABG. Company plans to submit for FDA De Novo and Health Canada marketing approvals in Q3 2024.
DYAI: Product Revenues Next Year
- Dyadic has developed C1, its proprietary fungal expression system that can produce a variety of recombinant proteins.
- C1 has been commercialized in industrial applications and is in development for production of pharmaceutical grade proteins.
- C1 exhibits potential to economically produce biologic vaccines, virus like particles, antibodies, Fc-fusion, enzymes, AAVs and other biopharmaceuticals.
AMS: 1Q24 Revenue Up, With Rhode Island Centers Coming on Stream in 2Q
- Revenue in 1Q24 advanced 5.9% y/y, driven by 14.5% & 38.4% respective improvements in PBRT and direct patient revenue, the latter due to international operations where patient volumes continue to increase.
- Ecuador’s recently installed new Gamma Knife ICON and Peru’s Gamma Knife represent the only Gamma Knife machines in these markets.
- AMS has indicated that its sales pipeline is the strongest it has been in years & revenue backlog has reached more than $210M, more than double the level at YE 2023.
LTRN: Expanding Horizons into Asia
- Lantern Pharma uses AI & data to identify drug responders, uncover mechanism of action & rescue failed drugs.
- It is developing LP-300 for non- & never smoker NSCLC in the Harmonic trial.
- Secondary candidates include LP-100 for mCRPC and LP-184 and LP-284 which are in clinical development for multiple biomarker-defined tumors and hematological cancers, respectively.
Bio-Techne Corporation: Growth in the Cell and Gene Therapy Market & Improved Positioning In Spatial Biology Market! – Major Drivers
- Bio-Techne Corporation, a biotech firm specializing in protein and cell-based research, recently reported their third quarter 2024 earnings.
- The company displayed strong performance, and its financial circumstances seem to be stabilizing.
- Bio-Techne’s 2% year-over-year organic revenue growth exceeded their expectations, heralding potential expansion as biotech funding and macroeconomic challenges in China stabilize.
Jazz Pharmaceuticals plc: Zanidatamab’s Differentiated Efficacy and Safety Profile & Other Major Drivers
- In the Q1 2024 earnings, Jazz Pharmaceuticals reported a year-over-year combined double-digit revenue growth from its key growth drivers including Xywav, Epidiolex, and Rylaze.
- These assets have significantly contributed to their first-quarter total revenue growth which reached over $900 million.
- Xywav’s revenue growth rose to 14% year-over-year, signifying the company’s positive trajectory and endurance in the market.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
